Get started

Alibaba

Technical Analysis Of 10 Mentioned Stocks!Hi, Long time no see! ;) Actually, quite a busy time but still, have some old depths again and here they are - the stocks you mentioned in the comment section. Probably you don't even remember them :) Sadly this series is not popular amongst crypto followers but still got enough data to sort out some stocks which may indicate that technically we get short-term bounces from shown areas. To be said, it is the only technical side, fundamental analysis is your homework to do. These aren't my picks, these are your mentioned stocks. Remember - fundamental analysis showing what to buy, technical analysis showing when to buy. So, do your homework and select what to buy ;) 1. Adobe 2. Alibaba 3. NVIDIA 4. Ball Corporation 5. Block 6. JD.com 7. Ford 8. CRISPR Therapeutics 9. Intel 10. PayPal If you were interested in anything, go and do your homework! ;) Regards, Vaido
NASDAQ:TSLA
by VaidoVeek
3
Alibaba Analysis 01.02.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:BABA
by basictradingtv
10
BABA Back at Median Line after distibutionHello Traders, Here is an analysis on Alibaba. As you can see in the chart Baba has completed a Wyckoff cycle of accumulation and distribution. Now that the price action is back at the median line it seems to be forming a triple bottom base and taking a break from its recent sell off. We will want to see more bullish volume grow in this area to confirm this base before looking for any buying opportunities. As the price action sits on the baseline in the middle of the structure the longer it holds the stonger it becomes and a buying opporitunity will approach. Patience is the only key to opening the door to profits. Savvy
NYSE:BABA
by Savvythe1
4
Has BABA hit the rock bottom? Technical analysis used is called Elliott Wave technical analysis. We can see an almost textbook 5 waves movement down. I have done a quick check of the validity of the count, based on the rules and: 1. Wave 2 never moves the start of Wave 1 2. Wave 3 is not the shortest out of the 3 impulse waves W1,W3,W5 3. Wave 4 never enters the price territory of Wave 1 All checked out confirming the validity of the count. The Fibonacci sequence is the mathematical basis of Elliott Wave Analysis.Based on that and on the guidelines I can see two scenarios for Alibaba and the ending of Wave 5 1. Scenario Nr 1 - Wave 5 ending where it is now. Based on the common Fib extension of 0.382 one of the most common one for Wave 5 . This one found support 3 times in the past month at this level. 2. Scenario Nr2 - Based on the guidelines when we have an impulse wave and Wave3 is the extended one, which is the case so far, Wave 5 and Wave 1 tend towards equality. This equality would happed, guess where at 0.618 golden ratio. I continue to be amazed by the precision of the Elliott Wave Model. Disclaimer: This is my analysis and does not constitute financial advice.
NYSE:BABA
by WavesInvesting
3
BABA | 2nd moveBABA... so much attention lately. Step 1 It would be pretty right to say, that most people have bought BABA at higher levels, 150-180$. This was before the big recent fall. This was step 1 - entering the stock before the collapse. Step 2 We are heading to the next step, which could be not very planned, but considering the circumstances, becomes necessary. Because of such a massive decrease of price, it's important to average the overall price, by buying more of the cheaper stock. It will yield eventually additional profit and compensate the initial higher price. A possible Step 3 Some are trying to guess the future, and where will the chart be in some months from now. Since we all know it's a useless task, the only realistic approach to handle current situation, is keep buying on each next significant price decrease. As example: Step 1 was made at 170$. Step 2 will be done at 100$ (if necessary) Step 3 at 70$ Knowing that BABA has a significant amount of cash, nearly no debts, positive and stable cash flow, good ratio indicators and 1 billion of active users - even if the stock will go to zero, it wouldn't change much. The company won't close, just because the stock worth less - they keep selling everyday. Besides, if the stock would reach 70$ at some point (which doubtful), it could be that for such a price, even those who don't trust BABA, will all run to buy such a discounted high quality product. Considering that 70-80$ does not seem as a realistic option, 100$ purchase is the best next possibility, which shouldn't be neglected. Let the BABA power be with us!
NYSE:BABA
by inducto
Alibaba Analysis 25.01.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:BABA
by basictradingtv
21
Alibaba signaling a reversal?BABA has spent the last year in a bear market. It's down about 60% from it's highs. Based on the charts, the sellers look exhausted and most of the downward momentum has been spent. There's bullish divergence on the daily and 4hr charts. It may take a couple months for bullish momentum to return in force, but it looks like we are at, or near the floor. I'm anticipating short-term bullishness followed by perhaps one more low, and then solid growth. ---------------------------------------------------------------- These are my personal views and not financial advice. Please do your own research before investing. I'd love to hear your thoughts, ideas and feedback. Feel free to Comment and I'll try and get back to you quickly. If you appreciated this analysis, consider Liking or Following . Thanks!
NYSE:BABALong
by mercury_rising
5
Alibaba Analysis 04.01.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:BABA
by basictradingtv
13
BABA - Alibaba Group Holding LtdBullish - Will require patience like my other trades. ( NYSE:BB NASDAQ:TLRY ) Previous Close 165.24 Open 159.99 Bid 159.56 x 800 Ask 159.57 x 800 Day's Range 158.56 - 161.74 52 Week Range 152.80 - 319.32 Volume 30,294,580 Avg. Volume 20,830,984 Market Cap 436.158B Beta (5Y Monthly) 0.81 PE Ratio (TTM) 19.25 EPS (TTM) 8.28 Earnings Date Nov 03, 2021 - Nov 08, 2021 1y Target Est 1,788.37 NYSE:BABA CAPITALCOM:BABA BCBA:BABA SIX:BABA MOEX:BABA-RM SWB:AHLA CAPITALCOM:9988 BCBA:BABA OTC:BABAF FTX:BABAUSD MYX:ALIBABA-C3 SWB:2RR BITTREX:BABAUSD
NYSE:BABALong
by MaverickTrading
Alibaba Analysis 21.12.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:BABA
by basictradingtv
10
Alibaba Healthcare Units Prepares for Next Battle in HealthcareAffected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. Alibaba (BABA:NASDAQ) is deemed to be the first explorer among Chinese tech giants, having joined the game as early as 1998 by founding Alibaba Health (0241:HK). In fact, it is the first Chinese Internet-healthcare company to go public on the Hong Kong Stock Exchange. Alibaba Health is primarily engaged in the pharmaceutical direct sales business, the pharmaceutical e-commerce platform business, medical and healthcare services platforms and digital infrastructure business and related services, though it wants to take off the 'e-pharmacy' tag for long. How does Alibaba compare in the healthcare endeavors? Financial Performance Alibaba Health finally became fully profitable in its fiscal 2021, when the revenue reached CNY 15.52 billion Among four major businesses, medicine remains the main contributor to its revenue, amounting to CNY 13.21 billion, or about 85% of the total revenue. The rest is contributed by pharmaceutical e-commerce platform business, the medical health service business and digital infrastructure business, with revenues of CNY 1.96 billion, CNY 284 million and CNY 53 million respectively. Benefiting from the improving cost control ability and the emerging economies of scale, the overall expenses of Alibaba Health are far less than that of JD Health for every comparable fiscal year. BABA's backing is the ace card of Alibaba Health As the healthcare business arm of Alibaba Group, the natural traffic comes with related brand benefits; Alibaba Health's core pharmaceutical direct sales and e-commerce platform businesses are thus boosted to a great extent. Three specific edges are worth mentioning. First, brand power drives growth. In 2021, Alibaba has grown its brand value by 32% year-on-year to USD 201.86 billion, with a 2nd ranking domestically and 7th ranking globally. As one of the most valuable brands, consumers are more likely to pay a value premium for the products with this recognizable name, or for the creditability it owns. This is indeed what is going on with Alibaba Health. For the 12 months ended March 31, 2021, the revenue from drugs generated from the pharmaceutical direct sales business under the brand of 'Alibaba Health' increased by 86.1% year-on-year, accounting for 64.8% of the revenue of the business. And the number of annual active users of the direct online stores in the reporting period reached a record high of 81 million. Second, synergistic benefits of Alibaba's ecosystem. The synergy effect is most difficult or even impossible to be imitated by competitors. When looking back at Alibaba's business scope, we could see it has already laid out a lot – Alipay's insurance services and 'Future Hospital' plan, O2O medicine delivery service on takeaway platform and hospital-specialized modules on DingTalk – most major businesses owned by Alibaba have medical-related s. With continuous investment in these business-to-consumer marketplace made by the Group, Alibaba Health is able to enhance health awareness and acquire new customers at relatively low acquisition costs, which lays a strong foundation for future growth. As of March 31, 2021, the number of annual active users had exceeded 280 million on Tmall's Pharmaceutical Platform while Alipay's healthcare channel as a whole reached over 520 million annual active users for the fiscal year. Third, empowerment of big data. As a wholly-owned subsidiary of Alibaba with deep roots in the Internet, Alibaba Health's capabilities and resources are naturally geared towards leveraging the prowess of the Internet, big data and Cloud computing. To further boost its digital infrastructure business, for example, tracking platform 'Ma Shang Fang Xin' and digital health business, Alibaba Health has been working closely with Alibaba Cloud to lead the healthcare area. In addition, it also focuses on digital infrastructure. Based on the Group's internal AI, big data, payment and IT capabilities, Alibaba Health is working on exploring the construction of intelligent medical systems, such as AI-assisted diagnostic decision-making, remote imaging platforms and blockchain data security solutions in major hospitals and regions. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:241
by EqualOcean